Customs clearance guarantee Tirzepatide Hot Sale Purity 99% Factory Delivery Super Low Price 10mg 30mg

Semaglutide---weight loss

Semaglutide has opened a new era of weight management for patients with type 2 diabetes, marking a shift in the treatment model for obesity, and its weight loss effect is close to that of bariatric surgery. In addition to weight loss, the overall health of patients has improved, and their physical function scores, blood pressure, and blood sugar have all been significantly improved.
Introduction
Semaglutide is a new generation of GLP-1 (glucagon-like peptide-1) analogs developed by Novo Nordisk of Denmark. Semaglutide is a long-acting formulation developed based on the basic structure of liraglutide, and its effect in treating type 2 diabetes is better. Novo Nordisk has completed six Phase IIIa studies of semaglutide injection, and has submitted a new drug registration application for semaglutide once-weekly injection to the U.S. Food and Drug Administration (FDA) on December 5, 2016, and also submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA). On the other hand, the once-daily oral formulation of semaglutide is currently in Phase III clinical trials.
Effects
Semaglutide is a long-acting formulation developed based on the basic structure of liraglutide, and its effect in treating type 2 diabetes is better. Semaglutide is prepared by solid-liquid phase synthesis. The linear peptide Aib8, Arg34GLP-1 (7-37) and fatty side chain acylating agent are prepared by solid phase synthesis. The linear peptide Lys26 is modified with the synthetic fatty chain acylating agent under alkaline conditions to obtain semaglutide, and the bioactivity of the homemade samples is determined by time-resolved fluorescence resonance energy transfer immunoassay.